ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Sells $555,000.00 in Stock

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Laura Shawver sold 50,000 shares of the stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $11.10, for a total transaction of $555,000.00. Following the completion of the sale, the director now owns 210,346 shares of the company’s stock, valued at approximately $2,334,840.60. The trade was a 19.21 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Laura Shawver also recently made the following trade(s):

• On Monday, December 2nd, Laura Shawver sold 97,244 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $13.56, for a total value of $1,318,628.64.
• On Wednesday, December 4th, Laura Shawver sold 14,772 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $13.75, for a total value of $203,115.00.

ARS Pharmaceuticals Price Performance

NASDAQ SPRY opened at $11.43 on Friday. The stock has a market capitalization of $1.11 billion, a P/E ratio of -22.41 and a beta of 0.96. The firm’s 50-day moving average is $13.11 and its two-hundred day moving average is $12.67. ARS Pharmaceuticals, Inc. has a 12 month low of $5.68 and a 12 month high of $18.51.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on SPRY shares. Cantor Fitzgerald reissued an “overweight” rating and set a $30.00 price target on shares of ARS Pharmaceuticals in a research report on Tuesday, October 8th. Leerink Partners boosted their target price on shares of ARS Pharmaceuticals from $21.00 to $25.00 and gave the company an “outperform” rating in a report on Friday, September 20th. Four equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $24.00.

Hedge Funds Weigh In On ARS Pharmaceuticals

Several large investors have recently made changes to their positions in the stock. J.W. Cole Advisors Inc. lifted its stake in ARS Pharmaceuticals by 10.8% during the second quarter. J.W. Cole Advisors Inc. now owns 15,400 shares of the company’s stock worth $131,000 after purchasing an additional 1,500 shares in the last quarter. nVerses Capital LLC acquired a new position in ARS Pharmaceuticals during the 3rd quarter worth about $30,000. Creative Planning boosted its holdings in ARS Pharmaceuticals by 7.0% during the 3rd quarter. Creative Planning now owns 35,263 shares of the company’s stock valued at $511,000 after acquiring an additional 2,307 shares during the period. HighTower Advisors LLC grew its position in ARS Pharmaceuticals by 18.2% in the 3rd quarter. HighTower Advisors LLC now owns 28,310 shares of the company’s stock valued at $411,000 after acquiring an additional 4,369 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in ARS Pharmaceuticals by 151.7% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,419 shares of the company’s stock worth $63,000 after purchasing an additional 4,472 shares during the period. 68.16% of the stock is currently owned by institutional investors and hedge funds.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.